Primavera: immunobiotics for treating early stage Age-related Macular Degeneration (AMD)

Projektinformationen

Primavera

ID Finanzhilfevereinbarung: 827213

DOI

10.3030/827213

Projekt abgeschlossen

EK-Unterschriftsdatum 13 Juli 2018

Startdatum 1 August 2018

Enddatum 31 Januar 2019

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

NUTRIPHARMA HUNGARIA TAP ES GYOGYSZER ELOALLITO KFT
Hungary

Periodic Reporting for period 1 - Primavera (Primavera: immunobiotics for treating early stage Age-related Macular Degeneration (AMD))

Berichtszeitraum: 2018-08-01 bis 2019-01-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Age-related Macular Degeneration (AMD) is a chronic, progressive, sight-threatening disease, caused by the damage of the macula, the small, central area of the retina. People with AMD have difficulty seeing colours, details and later, to read, to drive and to work. The disease causes significant social, medical, and economic burden. Its prevalence (hidden in early stage) is estimated more 8-10% in industrialized countries (EU, USA) for people over 40 years. However, neither screening method is proposed for the early detection of AMD nor its effective treatment has been approved yet. The multivitamin products, found on the market today, have proven low efficiency to supress early stage AMD, and rather expensive compared to their low-effectiveness.
The objective of the Primavera project is the commercialisation of a new medical food for treatment of AMD. Our unique formula, Primavera, is based on immunobiotic compounds, prepared by our innovative technology, and metabolic booster compounds. The formula will expectedly have benefits on both visual functions and retinal alterations in early AMD.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

In the present feasibility study, we examined the technological and market feasibility of Primavera as well as assessed the risks of our project. Based on our experiences and the relevant background scientific results we have drafted a clinical study plan that includes further trials and services that will be the main reference and starting point for the commercialization process. We have updated our preliminary market and competitor assessment and drafted a detailed business plan with professional assistance. Potential risks were covered with adequate contingency plans while our IP protection activities continued.
We concluded that the project is technologically feasible and economically reliable therefore we will continue our efforts to take Primavera to the market and make it a successful treatment that would massively help the society to prevent visual loss and treat early-stage macular degeneration.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Our Primavera product is based on our patented formula that is superior to the state of the art solutions which is proven via several scientific studies. Primavera, contains a mixture of immunobiotic compounds, synergistic vitamins and other supplements. The patented PROSYMBIO TECHNOLOGY® is now granted at EU level, while the grant is pending in China and in the USA, too. Upon the completion of a Phase 2 project it is expected that Primavera becomes market leader as it will provide an effective treatment in preventing visual loss caused by AMD. Patients using ineffective treatments before will perceive improvement in their visual function once taking the Primavera treatment.
The success of the project will contribute to the well-being (well aging) of European citizens. Regarding our company, the success of the project would promote our growth.

primavera-ph1report-image.jpg